The ISLAND Study: InSuLa Assessed Needs for Depression
| Status: | Recruiting |
|---|---|
| Conditions: | Depression, Depression |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 11/18/2018 |
| Start Date: | September 2014 |
| End Date: | June 2019 |
| Contact: | Tanja C Mletzko Crowe, MA |
| Email: | tmletzk@emory.edu |
| Phone: | 404-712-5063 |
Testing an Imaging Biomarker for Treatment Stratification in Major Depression
While there are many effective options for treating a major depressive episode, there are no
clinical markers that predict the likelihood of remission with an initial trial of either an
antidepressant medication or psychotherapy. The goal of this study is to test how brain
function changes in depress patients treated with cognitive behavioral therapy (CBT) compared
to patients treated with escitalopram ((s-CIT) - Lexapro®), an FDA approved antidepressant.
The study aims to determine if bran scan findings might help physicians to select the most
effective antidepressant treatment for an individual patient.
At total of 150 male and female outpatients who are between 21-55 years old will be enrolled.
Participation in the study will last from 14-26 weeks.
Subjects will be randomized to receive either escitalopram (s-CIT) or CBT for 12 weeks.
Resting-state positron emission tomography (PET) and BOLD functional magnetic resonance
imaging (fMRI) scans will be done before the treatment begins, and again at the end of
treatment (week 12). Non-responders to s-cIT or CBT will be crossed over to receive an
additional 12 weeks of treatment with the alternative intervention.
clinical markers that predict the likelihood of remission with an initial trial of either an
antidepressant medication or psychotherapy. The goal of this study is to test how brain
function changes in depress patients treated with cognitive behavioral therapy (CBT) compared
to patients treated with escitalopram ((s-CIT) - Lexapro®), an FDA approved antidepressant.
The study aims to determine if bran scan findings might help physicians to select the most
effective antidepressant treatment for an individual patient.
At total of 150 male and female outpatients who are between 21-55 years old will be enrolled.
Participation in the study will last from 14-26 weeks.
Subjects will be randomized to receive either escitalopram (s-CIT) or CBT for 12 weeks.
Resting-state positron emission tomography (PET) and BOLD functional magnetic resonance
imaging (fMRI) scans will be done before the treatment begins, and again at the end of
treatment (week 12). Non-responders to s-cIT or CBT will be crossed over to receive an
additional 12 weeks of treatment with the alternative intervention.
Inclusion Criteria:
1. Men or women aged 18-60 years.
2. Primary psychiatric diagnosis of Major Depressive Disorder, without psychotic
features, confirmed via SCID-IV structured diagnostic interview.
3. Screening Hamilton Depression Rating Scale (HAMD) ≥ 18; and Baseline HAMD ≥ 15.
4. If the patient is a woman of child-bearing potential, she must agree to use an
acceptable form of birth control for duration of study participation.
5. Able to understand and provide informed consent for participation.
Exclusion Criteria:
1. Lifetime history of Bipolar Disorder, Dementia, Autism Spectrum Disorder,
Schizophrenia, or any other Psychotic Disorder.
2. Psychotic symptoms occurring at any time during the current major depressive episode.
3. Current (past 12 months) diagnosis of Panic disorder, Obsessive Compulsive Disorder,
Posttraumatic Stress Disorder, Anorexia Nervosa, or Bulimia Nervosa.
4. Alcohol or Drug Dependence within 12 months or Abuse within 3 months (excluding
nicotine and caffeine) of baseline visit, as assessed by history and urine drug
screen.
5. Clinical evidence of a severe Personality Disorder, as assessed by the study
psychiatrist, which would impede participation or completion of the trial.
6. Known neurological disorders or documented serious head injury.
7. Serious and unstable medical illnesses including cardiovascular disease and cancer.
8. Active medical conditions with known mood changes (endocrine, autoimmune disorders).
9. Current diabetes mellitus.
10. For women, pregnancy, lactation, or unwillingness to comply with birth control
requirements.
11. Use of any of the following treatments or any other alternative therapy within 2 weeks
of the pre-treatment PET scan that may have beneficial effects on mood, including St
John's Wort, S-adenosyl methionine (SAMe), n-3 fatty acids, or light therapy.
12. Use of antidepressant medication within 1 month of the pre-treatment PET scan (within
5 weeks for fluoxetine and protryptyline).
13. Failure to achieve a much improved status (i.e. equivalent to >50% symptom reduction)
with any lifetime treatment course of CBT (defined as a minimum of 4 sessions of a
specified manual-driven therapy by a CBT-trained therapist) or escitalopram (defined
as a minimum of 6 weeks of at least 10 mg/day).
14. Clinically significant active suicidal ideation or self-injurious behavior
necessitating immediate treatment, as determined by the investigator.
15. Received electroconvulsive therapy in the past 6 months or during the current
depressive episode.
16. Currently responding to medication treatment, without clinical reasons to change.
17. Current treatment with weekly individual or group psychotherapy of any type targeted
at depressive symptoms.
18. QTc >500 milliseconds on EKG at screening.
19. Contraindications for MRI, including, but not limited to pacemaker, aneurysm clips,
neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine
devices for birth control.
20. Use of concomitant medications with the exception of:
- Maintenance or prophylactic therapy for stable medical conditions.
- Hypnotic medication prescribed or approved by the study physician, (up to a three
doses per week) for insomnia, as long if not the night before a PET/MRI or clinic
ratings visit. Antipsychotic medications, whether prescribed for sleep or other
indications, are prohibited.
We found this trial at
1
site
Atlanta, Georgia 30329
Principal Investigator: Boadie W Dunlop, MD/MS
Phone: 404-712-5063
Click here to add this to my saved trials
